Xeris Biopharma Holdings Inc XERS Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$15.20 up $2.12, 16.21% at close Nov 6
Last close · Previous close $13.08
- Market cap
- $2.62BAt the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$0.10Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$15.20up $2.12, 16.21%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$13.08Nov 5
- Volume7.90MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume3.01MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $5.25 to $15.21; now $15.20
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
XERS beat the S&P 500 in all 6 periods.
| Period | XERS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | XERS: up 50.9% S&P 500: down 5.6% | XERS beat the S&P 500 by 56.5 percentage points Beat |
| 3M | XERS: up 106.5% S&P 500: down 4.1% | XERS beat the S&P 500 by 110.6 percentage points Beat |
| YTD | XERS: up 93.6% S&P 500: up 8.7% | XERS beat the S&P 500 by 84.9 percentage points Beat |
| 1Y | XERS: up 97.1% S&P 500: up 10.9% | XERS beat the S&P 500 by 86.2 percentage points Beat |
| Long term | ||
| 3Y | XERS: up 721.6% S&P 500: up 75.0% +101.8% vs +20.5% a year | XERS beat the S&P 500 by 646.6 percentage points Beat |
| 5Y | XERS: up 679.5% S&P 500: up 67.8% +50.8% vs +10.9% a year | XERS beat the S&P 500 by 611.7 percentage points Beat |
$10,000 invested in XERS 5 years ago (Nov 5, 2021) would be worth about $77,949 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
XERS beat the S&P 500 in all 6 periods.
| Period | XERS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | XERS: up 50.9% S&P 500: down 5.6% | XERS beat the S&P 500 by 56.5 percentage points Beat |
| 3M | XERS: up 106.5% S&P 500: down 4.3% | XERS beat the S&P 500 by 110.8 percentage points Beat |
| YTD | XERS: up 93.6% S&P 500: up 7.8% | XERS beat the S&P 500 by 85.8 percentage points Beat |
| 1Y | XERS: up 97.1% S&P 500: up 9.7% | XERS beat the S&P 500 by 87.4 percentage points Beat |
| Long term | ||
| 3Y | XERS: up 721.6% S&P 500: up 68.8% +101.8% vs +19.1% a year | XERS beat the S&P 500 by 652.8 percentage points Beat |
| 5Y | XERS: up 679.5% S&P 500: up 56.9% +50.8% vs +9.4% a year | XERS beat the S&P 500 by 622.6 percentage points Beat |
$10,000 invested in XERS 5 years ago (Nov 5, 2021) would be worth about $77,949 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$27.23
Closing high on . Now 44.2% below that record.
Split-adjusted daily closes since Jun 21, 2018.
Stock splits
XERS hasn’t split since its price history begins in 2018.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$0.10 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 7.8×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 116.8×Last 12 months’ EBITDA
Enterprise value divided by EBITDA over the last 12 months. It compares companies with different amounts of debt.
EV/EBITDA = Enterprise value ÷ EBITDA (last 12 months)EV/EBITDA explained - 2.12%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $2.79BAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own XERS DCF in Excel. Value Xeris Biopharma Holdings with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $335.41Mup 36.3%
- Net income
- −$17.17M
- Diluted EPS
- −$0.10
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $54.27M | −$15.74M | −$0.11 |
| Q4 FY24 (Dec 31, 2024) | $60.10M | −$5.11M | −$0.03 |
| Q1 FY25 (Mar 31, 2025) | $60.12M | −$9.22M | −$0.06 |
| Q2 FY25 (Jun 30, 2025) | $71.54M | −$1.93M | −$0.01 |
| Q3 FY25 (Sep 30, 2025) | $74.38M | $621.00K | $0.00 |
| Q4 FY25 (Dec 31, 2025) | $85.81M | $11.08M | $0.07 |
| Q1 FY26 (Mar 31, 2026) | $83.13M | $2.23M | $0.01 |
| Q2 FY26 (Jun 30, 2026) | $92.10M | −$31.10M | −$0.18 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $49.59M | −$122.73M | −$1.55 |
| FY22 (Dec 31, 2022) | $110.25M | −$94.66M | −$0.70 |
| FY23 (Dec 31, 2023) | $163.91M | −$62.26M | −$0.45 |
| FY24 (Dec 31, 2024) | $203.07M | −$54.84M | −$0.37 |
| FY25 (Dec 31, 2025) | $291.85M | $554.00K | $0.00 |
Margins
- Gross 86.6%
- Operating 10.9%
- Net −5.1%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $55.67MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$56.61MLast 12 months
- Capital spending$938.00KLast 12 months
- 16.6%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $6.69MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
0% of free cash flow
Balance sheet
- $121.75MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$289.44MAs of Jun 30, 2026
- Net debt$167.70MAs of Jun 30, 2026
- 1.45As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- 6 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✓Operating cash flow was positive: passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −426.3%Last 12 months
Over the last 12 months, Xeris Biopharma Holdings lost money: its net loss was 426.3% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −4.4%Last 12 months
Over the last 12 months, Xeris Biopharma Holdings’s net loss was 4.4% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Xeris Biopharma Holdings Inc
Xeris is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke ®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis ®, a proven therapy for primary periodic paralysis; and Recorlev ® for the treatment of endogenous Cushing’s syndrome. Xeris has a diverse pipeline of development and partnered programs using its formulation sciences, XeriSol™ and XeriJect ®, to support long-term product development and commercial success. Xeris Biopharma Holdings is headquartered in Chicago, IL.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Illinois, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
XERS news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
XERS stock FAQ
What is XERS stock’s price today?
Xeris Biopharma Holdings (XERS) traded at $15.20 at the close on , up $2.12 (16.21%) from the previous close of $13.08. Over the past 52 weeks it has traded between $5.25 and $15.21.
If you invested $1,000 in XERS 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in XERS on would be worth about $7,795 at the close on , a total return of +679.5%. The same $1,000 would be worth $1,971 if invested one year ago. Past performance doesn’t predict future returns.
What is Xeris Biopharma Holdings’s market cap?
Xeris Biopharma Holdings’s market capitalization is about $2.6 billion. That’s Tiingo’s daily market cap for , at that day’s closing price of $15.20 (how market cap works). Xeris Biopharma Holdings reported 172.64M shares outstanding at the end of its latest quarter ().
What is XERS’s P/E ratio?
XERS’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$0.10).
How much revenue does Xeris Biopharma Holdings make?
Xeris Biopharma Holdings reported $335.4 million of revenue over the four quarters to , up 36.3% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $92.1 million, up 28.7% from a year earlier.
Is Xeris Biopharma Holdings profitable?
Not over the four quarters to . Xeris Biopharma Holdings reported a net loss of $17.2 million across those four quarters on $335.4 million of revenue. Its operations were still profitable before interest, other items and taxes, with $36.6 million of operating income.
What are XERS’s earnings per share?
XERS’s diluted earnings per share were −$0.10 over the four quarters to , compared with −$0.21 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.18 per share, against −$0.01 a year earlier (how EPS works).
Does XERS pay a dividend?
Xeris Biopharma Holdings hasn’t paid a dividend in the last twelve months.
What is XERS’s 52-week high and low?
Over the past 52 weeks XERS has traded as low as $5.25 and as high as $15.21. At $15.20 at the close on , it is 0.1% below that high and 189.5% above the low.
What is XERS’s all-time high?
XERS’s highest closing price was $27.23 on , adjusted for stock splits. At $15.20 at the close on , it is 44.2% below that record.
Has XERS stock ever split?
No. XERS hasn’t split since its price history begins in 2018.
How has XERS stock performed?
Including dividends and measured to the close on , XERS has returned +93.6% so far this year and +97.1% over the past year, and +679.5% over five years (+50.8% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Xeris Biopharma Holdings in?
Xeris Biopharma Holdings is in the Healthcare sector and the Biotechnology industry, and is headquartered in Illinois, USA.
What exchange does XERS trade on?
Xeris Biopharma Holdings trades on the Nasdaq under the ticker symbol XERS. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.